Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-31

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an exploratory study to determine the safety and clinical benefit of OMS302 Injection in subjects undergoing Cataract Extraction with Lens Replacement (CELR) using a coaxial phacoemulsification process.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

NCT01193127

Cataract

COMPLETED PHASE2

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01579565

Intraocular Lens Replacement

COMPLETED PHASE3

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01454063

Intraocular Lens Replacement

COMPLETED PHASE3

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement

NCT02132312

Unilateral Cataract Extraction Congenital Cataract

COMPLETED PHASE3

Safety and Tolerability of EO2002

NCT05587205

Cataract Endothelial Cell Loss, Corneal

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OMS302 Injection is a mydriatic/anti-inflammatory combination investigational drug product being developed as an irrigation solution during intracameral lens replacement surgical procedures of the eye. OMS302 irrigation solution may induce and maintain an adequately dilated pupil and reduce postoperative symptoms of discomfort such as eye pain and irritation. The use of OMS302 irrigation solution may eliminate the need for pre-operative dilation of the eye and could reduce the postoperative use of an anti-inflammatory and pain medications following surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract Extraction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

OMS302 Irrigation Solution

Group Type EXPERIMENTAL

OMS302

Intervention Type DRUG

OMS302 Irrigation Solution

2

OMS302-PE HCl Irrigation Solution

Group Type ACTIVE_COMPARATOR

OMS302-PE

Intervention Type DRUG

OMS302-PE HCI Irrigation Solution

3

Standard topical mydriatics and BSS Irrigation Solution

Group Type PLACEBO_COMPARATOR

Vehicle

Intervention Type DRUG

Standard topical mydriatics and Balanced Salt Solution Irrigation Solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OMS302

OMS302 Irrigation Solution

Intervention Type DRUG

OMS302-PE

OMS302-PE HCI Irrigation Solution

Intervention Type DRUG

Vehicle

Standard topical mydriatics and Balanced Salt Solution Irrigation Solution

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OMS302 Irrigation Solution OMS302-PE HCI Irrigation Solution Standard topical mydriatics and Balanced Salt Solution Irrigation Solution

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is 50 years of age or older.
* Subject is to undergo unilateral primary CELR for an age-related cataract under topical anesthesia and using a clear cornea incision.
* Subject's history and physical examination are within normal limits or the examination is clinically non-significant for purposes of the study as determined by the Investigator, and subject is in good general health.
* Subject has best corrected visual acuity (BCVA) of 20/400 or better in the non-study eye.
* Subject has intraocular pressure (IOP) between 5 mmHg and 22 mmHg, inclusive, in the study eye.

Exclusion Criteria

* Subject is allergic to any of the individual ingredients in OMS302
* Subject who is taking medications with the same activities as that of the active ingredients in OMS302 for defined time intervals prior to and after surgery.
* Female subject of childbearing potential (i.e., not surgically sterilized nor post-menopausal longer than one year) who is not using an effective method of birth control within at least 14 days prior to surgery or has a positive pregnancy test.
* Subject who has a present condition or history of any clinically significant uncontrolled gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, connective tissue, respiratory, or medical disorder as determined by the Investigator.
* Subject who is taking anticoagulants.
* Subject who is taking or needs to take for the duration of the study any of the prohibited medications.
* Subject with pseudo-capsular exfoliation, or evidence of prior iritis or of ocular trauma with iris damage, or who has used pilocarpine within six months of screening.
* Subject that has uncontrolled chronic ocular disease.
* Subject that has active corneal pathology or scarring noted in either eye (except superficial punctate keratopathy in the non-study eye).
* Subject that has extraocular/intraocular inflammation in either eye.
* Subject has an active bacterial and/or viral infection in either eye.
* Subject that has narrow-angle glaucoma, unstable glaucoma, or glaucoma being treated with prostaglandins or prostaglandin analogues.
* Subject taking, or has taken within the past year, an alpha adrenergic antagonist.
* Subject that has participated in or is currently participating in any investigational drug or device trial within the previous 30 days prior to the day of surgery.
* Subject that has had intraocular conventional surgery within the past three months or intraocular laser surgery within one month of the planned surgery in the study eye.
* Subject that requires the use of other topical medications during the trial except prophylactic antibiotics, topical lid care or glaucoma medications or tear replacement solutions.
* Subject that needs other ocular surgery at the time of the cataract extraction.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No